Bill Text: TX SB2176 | 2017-2018 | 85th Legislature | Comm Sub
Bill Title: Relating to the placement of certain substances in Penalty Groups 1 and 3 of the Texas Controlled Substances Act for the purposes of prosecution of criminal offenses involving those substances.
Sponsorship: Partisan Bill (Republican 1)
Status: (Introduced - Dead) 2017-04-18 - Committee report printed and distributed [SB2176 Detail]
Download: Texas-2017-SB2176-Comm_Sub.html
| By: Hughes | S.B. No. 2176 | |
| (In the Senate - Filed March 10, 2017; March 29, 2017, read | ||
| first time and referred to Committee on Criminal Justice; | ||
| April 18, 2017, reported adversely, with favorable Committee | ||
| Substitute by the following vote: Yeas 7, Nays 0; April 18, 2017, | ||
| sent to printer.) | ||
| COMMITTEE SUBSTITUTE FOR S.B. No. 2176 | By: Whitmire | |
|
|
||
|
|
||
| relating to the placement of certain substances in Penalty Groups 1 | ||
| and 3 of the Texas Controlled Substances Act for the purposes of | ||
| prosecution of criminal offenses involving those substances. | ||
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
| SECTION 1. Section 481.102, Health and Safety Code, is | ||
| amended to read as follows: | ||
| Sec. 481.102. PENALTY GROUP 1. Penalty Group 1 consists of: | ||
| (1) the following opiates, including their isomers, | ||
| esters, ethers, salts, and salts of isomers, esters, and ethers, | ||
| unless specifically excepted, if the existence of these isomers, | ||
| esters, ethers, and salts is possible within the specific chemical | ||
| designation: | ||
| Alfentanil; | ||
| Allylprodine; | ||
| Alphacetylmethadol; | ||
| Benzethidine; | ||
| Betaprodine; | ||
| Clonitazene; | ||
| Diampromide; | ||
| Diethylthiambutene; | ||
| Difenoxin not listed in Penalty Group 3 or 4; | ||
| Dimenoxadol; | ||
| Dimethylthiambutene; | ||
| Dioxaphetyl butyrate; | ||
| Dipipanone; | ||
| Ethylmethylthiambutene; | ||
| Etonitazene; | ||
| Etoxeridine; | ||
| Furethidine; | ||
| Hydroxypethidine; | ||
| Ketobemidone; | ||
| Levophenacylmorphan; | ||
| Meprodine; | ||
| Methadol; | ||
| Moramide; | ||
| Morpheridine; | ||
| Noracymethadol; | ||
| Norlevorphanol; | ||
| Normethadone; | ||
| Norpipanone; | ||
| Phenadoxone; | ||
| Phenampromide; | ||
| Phenomorphan; | ||
| Phenoperidine; | ||
| Piritramide; | ||
| Proheptazine; | ||
| Properidine; | ||
| Propiram; | ||
| Sufentanil; | ||
| Tilidine; and | ||
| Trimeperidine; | ||
| (2) the following opium derivatives, their salts, | ||
| isomers, and salts of isomers, unless specifically excepted, if the | ||
| existence of these salts, isomers, and salts of isomers is possible | ||
| within the specific chemical designation: | ||
| Acetorphine; | ||
| Acetyldihydrocodeine; | ||
| Benzylmorphine; | ||
| Codeine methylbromide; | ||
| Codeine-N-Oxide; | ||
| Cyprenorphine; | ||
| Desomorphine; | ||
| Dihydromorphine; | ||
| Drotebanol; | ||
| Etorphine, except hydrochloride salt; | ||
| Heroin; | ||
| Hydromorphinol; | ||
| Methyldesorphine; | ||
| Methyldihydromorphine; | ||
| Monoacetylmorphine; | ||
| Morphine methylbromide; | ||
| Morphine methylsulfonate; | ||
| Morphine-N-Oxide; | ||
| Myrophine; | ||
| Nicocodeine; | ||
| Nicomorphine; | ||
| Normorphine; | ||
| Pholcodine; and | ||
| Thebacon; | ||
| (3) the following substances, however produced, | ||
| except those narcotic drugs listed in another group: | ||
| (A) Opium and opiate not listed in Penalty Group | ||
| 3 or 4, and a salt, compound, derivative, or preparation of opium or | ||
| opiate, other than thebaine derived butorphanol, nalmefene and its | ||
| salts, naloxone and its salts, and naltrexone and its salts, but | ||
| including: | ||
| Codeine not listed in Penalty Group 3 or 4; | ||
| Dihydroetorphine; | ||
| Ethylmorphine not listed in Penalty Group 3 | ||
| or 4; | ||
| Granulated opium; | ||
| Hydrocodone not listed in Penalty Group 3; | ||
| Hydromorphone; | ||
| Metopon; | ||
| Morphine not listed in Penalty Group 3; | ||
| Opium extracts; | ||
| Opium fluid extracts; | ||
| Oripavine; | ||
| Oxycodone; | ||
| Oxymorphone; | ||
| Powdered opium; | ||
| Raw opium; | ||
| Thebaine; and | ||
| Tincture of opium; | ||
| (B) a salt, compound, isomer, derivative, or | ||
| preparation of a substance that is chemically equivalent or | ||
| identical to a substance described by Paragraph (A), other than the | ||
| isoquinoline alkaloids of opium; | ||
| (C) Opium poppy and poppy straw; | ||
| (D) Cocaine, including: | ||
| (i) its salts, its optical, position, and | ||
| geometric isomers, and the salts of those isomers; | ||
| (ii) coca leaves and a salt, compound, | ||
| derivative, or preparation of coca leaves; and | ||
| (iii) a salt, compound, derivative, or | ||
| preparation of a salt, compound, or derivative that is chemically | ||
| equivalent or identical to a substance described by Subparagraph | ||
| (i) or (ii), other than decocainized coca leaves or extractions of | ||
| coca leaves that do not contain cocaine or ecgonine; and | ||
| (E) concentrate of poppy straw, meaning the crude | ||
| extract of poppy straw in liquid, solid, or powder form that | ||
| contains the phenanthrine alkaloids of the opium poppy; | ||
| (4) the following opiates, including their isomers, | ||
| esters, ethers, salts, and salts of isomers, if the existence of | ||
| these isomers, esters, ethers, and salts is possible within the | ||
| specific chemical designation: | ||
| Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2- | ||
| phenethyl)-4-piperidinyl]-N-phenylacetamide); | ||
| Alpha-methylthiofentanyl (N-[1-methyl-2-(2- | ||
| thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); | ||
| Alphaprodine; | ||
| Anileridine; | ||
| Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2- | ||
| phenethyl)-4-piperidinyl] -N-phenylpropanamide); | ||
| Beta-hydroxy-3-methylfentanyl; | ||
| Bezitramide; | ||
| Carfentanil; | ||
| Dihydrocodeine not listed in Penalty Group 3 or 4; | ||
| Diphenoxylate not listed in Penalty Group 3 or 4; | ||
| Fentanyl or alpha-methylfentanyl, or any other | ||
| derivative of Fentanyl; | ||
| Isomethadone; | ||
| Levomethorphan; | ||
| Levorphanol; | ||
| Metazocine; | ||
| Methadone; | ||
| Methadone-Intermediate, 4-cyano-2-dimethylamino- | ||
| 4, 4-diphenyl butane; | ||
| 3-methylfentanyl(N-[3-methyl-1-(2-phenylethyl)- | ||
| 4-piperidyl]-N-phenylpropanamide); | ||
| 3-methylthiofentanyl(N-[3-methyl-1-(2-thienyl) | ||
| ethyl-4-piperidinyl]-N-phenylpropanamide); | ||
| Moramide-Intermediate, 2-methyl-3-morpholino-1, | ||
| 1-diphenyl-propane-carboxylic acid; | ||
| Para-fluorofentanyl(N-(4-fluorophenyl)-N-1-(2- | ||
| phenylethyl)-4-piperidinylpropanamide); | ||
| PEPAP (1-(2-phenethyl)-4-phenyl-4- | ||
| acetoxypiperidine); | ||
| Pethidine (Meperidine); | ||
| Pethidine-Intermediate-A, 4-cyano-1-methyl-4- | ||
| phenylpiperidine; | ||
| Pethidine-Intermediate-B, ethyl-4- | ||
| phenylpiperidine-4 carboxylate; | ||
| Pethidine-Intermediate-C, 1-methyl-4- | ||
| phenylpiperidine-4-carboxylic acid; | ||
| Phenazocine; | ||
| Piminodine; | ||
| Racemethorphan; | ||
| Racemorphan; | ||
| Remifentanil; and | ||
| Thiofentanyl(N-phenyl-N-[1-(2-thienyl)ethyl-4-pi | ||
| peridinyl]-propanamide); | ||
| (5) Flunitrazepam (trade or other name: Rohypnol); | ||
| (6) Methamphetamine, including its salts, optical | ||
| isomers, and salts of optical isomers; | ||
| (7) Phenylacetone and methylamine, if possessed | ||
| together with intent to manufacture methamphetamine; | ||
| (8) Phencyclidine, including its salts; | ||
| (9) Gamma hydroxybutyric acid (some trade or other | ||
| names: gamma hydroxybutyrate, GHB), including its salts; [ |
||
| (10) Ketamine; | ||
| (11) Phenazepam; | ||
| (12) U-47700; and | ||
| (13) AH-7921. | ||
| SECTION 2. Section 481.104(a), Health and Safety Code, is | ||
| amended to read as follows: | ||
| (a) Penalty Group 3 consists of: | ||
| (1) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances having a | ||
| potential for abuse associated with a stimulant effect on the | ||
| central nervous system: | ||
| Methylphenidate and its salts; and | ||
| Phenmetrazine and its salts; | ||
| (2) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances having a | ||
| potential for abuse associated with a depressant effect on the | ||
| central nervous system: | ||
| a substance that contains any quantity of a | ||
| derivative of barbituric acid, or any salt of a derivative of | ||
| barbituric acid not otherwise described by this subsection; | ||
| a compound, mixture, or preparation containing | ||
| amobarbital, secobarbital, pentobarbital, or any salt of any of | ||
| these, and one or more active medicinal ingredients that are not | ||
| listed in any penalty group; | ||
| a suppository dosage form containing amobarbital, | ||
| secobarbital, pentobarbital, or any salt of any of these drugs, and | ||
| approved by the United States Food and Drug Administration for | ||
| marketing only as a suppository; | ||
| Alprazolam; | ||
| Amobarbital; | ||
| Bromazepam; | ||
| Camazepam; | ||
| Carisoprodol; | ||
| Chlordiazepoxide; | ||
| Chlorhexadol; | ||
| Clobazam; | ||
| Clonazepam; | ||
| Clorazepate; | ||
| Clotiazepam; | ||
| Cloxazolam; | ||
| Delorazepam; | ||
| Diazepam; | ||
| Estazolam; | ||
| Ethyl loflazepate; | ||
| Etizolam; | ||
| Fludiazepam; | ||
| Flurazepam; | ||
| Glutethimide; | ||
| Halazepam; | ||
| Haloxzolam; | ||
| Ketazolam; | ||
| Loprazolam; | ||
| Lorazepam; | ||
| Lormetazepam; | ||
| Lysergic acid, including its salts, isomers, and | ||
| salts of isomers; | ||
| Lysergic acid amide, including its salts, | ||
| isomers, and salts of isomers; | ||
| Mebutamate; | ||
| Medazepam; | ||
| Methyprylon; | ||
| Midazolam; | ||
| Nimetazepam; | ||
| Nitrazepam; | ||
| Nordiazepam; | ||
| Oxazepam; | ||
| Oxazolam; | ||
| Pentazocine, its salts, derivatives, or compounds | ||
| or mixtures thereof; | ||
| Pentobarbital; | ||
| Pinazepam; | ||
| Prazepam; | ||
| Quazepam; | ||
| Secobarbital; | ||
| Sulfondiethylmethane; | ||
| Sulfonethylmethane; | ||
| Sulfonmethane; | ||
| Temazepam; | ||
| Tetrazepam; | ||
| Tiletamine and zolazepam in combination, and its | ||
| salts. (some trade or other names for a tiletamine-zolazepam | ||
| combination product: Telazol, for tiletamine: 2-(ethylamino)- | ||
| 2-(2-thienyl)-cyclohexanone, and for zolazepam: 4-(2- | ||
| fluorophenyl)-6, 8-dihydro-1,3,8,-trimethylpyrazolo-[3,4- | ||
| e](1,4)-d diazepin-7(1H)-one, flupyrazapon); | ||
| Tramadol; | ||
| Triazolam; | ||
| Zaleplon; | ||
| Zolpidem; and | ||
| Zopiclone; | ||
| (3) Nalorphine; | ||
| (4) a material, compound, mixture, or preparation | ||
| containing limited quantities of the following narcotic drugs, or | ||
| any of their salts: | ||
| not more than 1.8 grams of codeine, or any of its | ||
| salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
| unit, with an equal or greater quantity of an isoquinoline alkaloid | ||
| of opium; | ||
| not more than 1.8 grams of codeine, or any of its | ||
| salts, per 100 milliliters or not more than 90 milligrams per dosage | ||
| unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 300 milligrams of dihydrocodeinone | ||
| (hydrocodone), or any of its salts, per 100 milliliters or not more | ||
| than 15 milligrams per dosage unit, with a fourfold or greater | ||
| quantity of an isoquinoline alkaloid of opium; | ||
| not more than 300 milligrams of dihydrocodeinone | ||
| (hydrocodone), or any of its salts, per 100 milliliters or not more | ||
| than 15 milligrams per dosage unit, with one or more active, | ||
| nonnarcotic ingredients in recognized therapeutic amounts; | ||
| not more than 1.8 grams of dihydrocodeine, or any | ||
| of its salts, per 100 milliliters or not more than 90 milligrams per | ||
| dosage unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 300 milligrams of ethylmorphine, or | ||
| any of its salts, per 100 milliliters or not more than 15 milligrams | ||
| per dosage unit, with one or more active, nonnarcotic ingredients | ||
| in recognized therapeutic amounts; | ||
| not more than 500 milligrams of opium per 100 | ||
| milliliters or per 100 grams, or not more than 25 milligrams per | ||
| dosage unit, with one or more active, nonnarcotic ingredients in | ||
| recognized therapeutic amounts; | ||
| not more than 50 milligrams of morphine, or any of | ||
| its salts, per 100 milliliters or per 100 grams with one or more | ||
| active, nonnarcotic ingredients in recognized therapeutic amounts; | ||
| and | ||
| not more than 1 milligram of difenoxin and not | ||
| less than 25 micrograms of atropine sulfate per dosage unit; | ||
| (5) a material, compound, mixture, or preparation that | ||
| contains any quantity of the following substances: | ||
| Barbital; | ||
| Chloral betaine; | ||
| Chloral hydrate; | ||
| Ethchlorvynol; | ||
| Ethinamate; | ||
| Meprobamate; | ||
| Methohexital; | ||
| Methylphenobarbital (Mephobarbital); | ||
| Paraldehyde; | ||
| Petrichloral; and | ||
| Phenobarbital; | ||
| (6) Peyote, unless unharvested and growing in its | ||
| natural state, meaning all parts of the plant classified | ||
| botanically as Lophophora, whether growing or not, the seeds of the | ||
| plant, an extract from a part of the plant, and every compound, | ||
| manufacture, salt, derivative, mixture, or preparation of the | ||
| plant, its seeds, or extracts; | ||
| (7) unless listed in another penalty group, a | ||
| material, compound, mixture, or preparation that contains any | ||
| quantity of the following substances having a stimulant effect on | ||
| the central nervous system, including the substance's salts, | ||
| optical, position, or geometric isomers, and salts of the | ||
| substance's isomers, if the existence of the salts, isomers, and | ||
| salts of isomers is possible within the specific chemical | ||
| designation: | ||
| Benzphetamine; | ||
| Cathine [(+)-norpseudoephedrine]; | ||
| Chlorphentermine; | ||
| Clortermine; | ||
| Diethylpropion; | ||
| Fencamfamin; | ||
| Fenfluramine; | ||
| Fenproporex; | ||
| Mazindol; | ||
| Mefenorex; | ||
| Modafinil; | ||
| Pemoline (including organometallic complexes and | ||
| their chelates); | ||
| Phendimetrazine; | ||
| Phentermine; | ||
| Pipradrol; | ||
| Sibutramine; and | ||
| SPA [(-)-1-dimethylamino-1,2-diphenylethane]; | ||
| (8) unless specifically excepted or unless listed in | ||
| another penalty group, a material, compound, mixture, or | ||
| preparation that contains any quantity of the following substance, | ||
| including its salts: | ||
| Dextropropoxyphene (Alpha-(+)-4-dimethylamino- | ||
| 1,2-diphenyl-3-methyl-2-propionoxybutane); | ||
| (9) an anabolic steroid, including any drug or | ||
| hormonal substance, or any substance that is chemically or | ||
| pharmacologically related to testosterone, other than an estrogen, | ||
| progestin, dehydroepiandrosterone, or corticosteroid, and promotes | ||
| muscle growth, including the following drugs and substances and any | ||
| salt, ester, or ether of the following drugs and substances: | ||
| Androstanediol; | ||
| Androstanedione; | ||
| Androstenediol; | ||
| Androstenedione; | ||
| Bolasterone; | ||
| Boldenone; | ||
| Calusterone; | ||
| Clostebol; | ||
| Dehydrochlormethyltestosterone; | ||
| Delta-1-dihydrotestosterone; | ||
| Dihydrotestosterone (4-dihydrotestosterone); | ||
| Drostanolone; | ||
| Ethylestrenol; | ||
| Fluoxymesterone; | ||
| Formebulone; | ||
| Furazabol; | ||
| 13beta-ethyl-17beta-hydroxygon-4-en-3-one; | ||
| 4-hydroxytestosterone; | ||
| 4-hydroxy-19-nortestosterone; | ||
| Mestanolone; | ||
| Mesterolone; | ||
| Methandienone; | ||
| Methandriol; | ||
| Methenolone; | ||
| 17alpha-methyl-3beta, 17 beta-dihydroxy-5alpha- | ||
| androstane; | ||
| 17alpha-methyl-3alpha, 17 beta-dihydroxy-5alpha- | ||
| androstane; | ||
| 17alpha-methyl-3beta, 17beta-dihydroxyandrost-4- | ||
| ene; | ||
| 17alpha-methyl-4-hydroxynandrolone; | ||
| Methyldienolone; | ||
| Methyltestosterone; | ||
| Methyltrienolone; | ||
| 17alpha-methyl-delta-1-dihydrotestosterone; | ||
| Mibolerone; | ||
| Nandrolone; | ||
| Norandrostenediol; | ||
| Norandrostenedione; | ||
| Norbolethone; | ||
| Norclostebol; | ||
| Norethandrolone; | ||
| Normethandrolone; | ||
| Oxandrolone; | ||
| Oxymesterone; | ||
| Oxymetholone; | ||
| Stanozolol; | ||
| Stenbolone; | ||
| Testolactone; | ||
| Testosterone; | ||
| Tetrahydrogestrinone; and | ||
| Trenbolone; and | ||
| (10) Salvia divinorum, unless unharvested and growing | ||
| in its natural state, meaning all parts of that plant, whether | ||
| growing or not, the seeds of that plant, an extract from a part of | ||
| that plant, and every compound, manufacture, salt, derivative, | ||
| mixture, or preparation of that plant, its seeds, or extracts, | ||
| including Salvinorin A. | ||
| SECTION 3. The change in law made by this Act applies only | ||
| to an offense committed on or after the effective date of this Act. | ||
| An offense committed before the effective date of this Act is | ||
| governed by the law in effect on the date the offense was committed, | ||
| and the former law is continued in effect for that purpose. For | ||
| purposes of this section, an offense was committed before the | ||
| effective date of this Act if any element of the offense occurred | ||
| before that date. | ||
| SECTION 4. This Act takes effect September 1, 2017. | ||
| * * * * * | ||
